Shortwave Life Sciences: Pioneering Mental Health Care
We are on a mission to change lives—and we need your support.
Shortwave Life Sciences is launching a crowdfunding campaign on Crowdcube to bring revolutionary new treatments to the forefront of mental health care, starting with eating disorders like anorexia nervosa.
Anorexia nervosa is the most fatal of all mental health conditions, with a 10% mortality rate and no FDA-approved pharmaceutical treatments. The need for innovative solutions is urgent, and Shortwave Life Sciences is stepping up to meet this challenge.
Our pioneering approach combines:
- Psilocybin-based drug innovation designed to address the unique complexities of anorexia nervosa.
- Proprietary buccal film delivery for enhanced patient adherence and superior therapeutic outcomes.
- Collaboration with Sheba Medical Center, a world leader in eating disorder treatment, to advance clinical trials.
By joining our campaign, you can directly support the development of life-changing treatments for patients who need them most while securing equity in a company at the forefront of mental health innovation.
The Future of Mental Health
At Shortwave Life Sciences, we’re driven by a focused and experienced leadership team with a wealth of knowledge in drug development, clinical research and strategy, particularly within the psychedelic field. Our first clinical program hones in on addressing anorexia nervosa, a life-threatening condition with no FDA-approved medication, where psilocybin shows promise as a breakthrough therapy. Leveraging established global partnerships across IP, drug development, market intelligence and investor relations, we’re poised to make significant strides in addressing unmet patient needs.
Rooted in the Israeli innovation ecosystem, our IP-driven approach capitalizes on unmatched knowledge and expertise. Through a strategic economic model combining in-house capabilities and strategic partnerships, we’ve optimized our drug discovery and development process to preserve capital and maximize efficiency. With a focus on our current programs and the addition of new IP opportunities, our team is dedicated to leveraging our unique platform to identify, operate, and create value from early-stage, breakthrough initiatives in the treatment of eating disorders and mental health.
